
|Videos|April 14, 2023
Should Men with Prior CVD be Treated Preferentially with a GnRH Antagonist?
Dr Higano provides a timeline review of safety results for GnH agonists and GnRH antagonists including the recent prospective phase 3 PRONOUNCE study for prostate cancer patients with pre-existing CV disease, followed by closing thoughts on this video series.
Advertisement
January 2023 AbbVie Inc. Company Confidential
Advertisement
Latest CME
Advertisement
Advertisement
Trending on Urology Times
1
HHS requests testosterone therapy label updates, citing new safety data
2
Unmet needs and emerging solutions in MRI-guided prostate cancer care
3
Pearls & Perspectives: The Power of Advocacy in Sexual Medicine, With Rachel Rubin, MD
4
Microbial dysbiosis may predict response to CBM588 in mRCC
5













